Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Atomo Diagnostics Ltd. ( (AU:AT1) ) just unveiled an announcement.
Atomo Diagnostics Limited announced it will release its Q2 FY25 Results on January 30, 2025, followed by a webinar hosted by Managing Director & CEO John Kelly. This announcement reflects Atomo’s ongoing commitment to transparency with its stakeholders and highlights its strategic positioning within the rapid diagnostic testing industry. The company’s focus on enhancing usability and reliability in testing devices supports its market presence in tackling infectious diseases.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Limited is an Australian-headquartered medical device company that supplies unique, integrated rapid diagnostic test devices to the global diagnostic market. The company’s patented devices simplify testing procedures, enhance usability, and improve reliability across rapid point-of-care and at-home testing applications. Atomo has commercialized various products internationally and holds supply agreements for testing applications targeting infectious diseases, including COVID-19, HIV, viral vs bacterial differentiation, and female health.
YTD Price Performance: 0%
Average Trading Volume: 218,958
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$12.14M
See more data about AT1 stock on TipRanks’ Stock Analysis page.
